Mitchell Scott Rein, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leiomyoma | 22 | 2001 | 730 | 1.080 |
Why?
|
| Uterine Neoplasms | 23 | 2001 | 1513 | 0.880 |
Why?
|
| Leuprolide | 16 | 1996 | 321 | 0.530 |
Why?
|
| Gonadotropin-Releasing Hormone | 10 | 2001 | 1205 | 0.340 |
Why?
|
| Progesterone | 5 | 2000 | 773 | 0.270 |
Why?
|
| Fertilization in Vitro | 9 | 1998 | 1283 | 0.230 |
Why?
|
| Receptors, Progesterone | 3 | 2000 | 1098 | 0.220 |
Why?
|
| Progestins | 4 | 2000 | 306 | 0.220 |
Why?
|
| Clostridium Infections | 2 | 2018 | 548 | 0.200 |
Why?
|
| Chromosome Aberrations | 4 | 1998 | 1811 | 0.190 |
Why?
|
| Hospitals, Community | 2 | 2018 | 347 | 0.170 |
Why?
|
| Uterus | 7 | 1994 | 711 | 0.170 |
Why?
|
| Cross Infection | 2 | 2018 | 1416 | 0.160 |
Why?
|
| Myometrium | 4 | 1994 | 181 | 0.160 |
Why?
|
| Prolactin | 4 | 1994 | 668 | 0.150 |
Why?
|
| Ovulation Induction | 2 | 1996 | 274 | 0.140 |
Why?
|
| Pregnancy, Multiple | 2 | 2003 | 217 | 0.140 |
Why?
|
| Menotropins | 3 | 1996 | 45 | 0.140 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2017 | 204 | 0.130 |
Why?
|
| Pregnancy, Ectopic | 3 | 1994 | 141 | 0.130 |
Why?
|
| Somatomedins | 2 | 1990 | 192 | 0.110 |
Why?
|
| Myoma | 1 | 1992 | 10 | 0.110 |
Why?
|
| Menstruation Disturbances | 1 | 1993 | 148 | 0.110 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 1990 | 272 | 0.100 |
Why?
|
| Embryo Transfer | 3 | 1998 | 510 | 0.100 |
Why?
|
| Karyotyping | 5 | 1998 | 1243 | 0.100 |
Why?
|
| Drug Utilization | 1 | 2017 | 1183 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1996 | 1950 | 0.080 |
Why?
|
| Triplets | 2 | 2003 | 43 | 0.080 |
Why?
|
| Estrogens | 5 | 1993 | 1563 | 0.080 |
Why?
|
| Dextrans | 1 | 1989 | 595 | 0.080 |
Why?
|
| Hospitals, Urban | 1 | 2009 | 499 | 0.080 |
Why?
|
| Economics, Hospital | 1 | 2009 | 213 | 0.070 |
Why?
|
| Embryo Implantation | 3 | 1998 | 272 | 0.070 |
Why?
|
| Quality Improvement | 2 | 2018 | 3750 | 0.070 |
Why?
|
| Estradiol | 9 | 1993 | 2017 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 1990 | 2017 | 0.070 |
Why?
|
| Translocation, Genetic | 3 | 1996 | 1420 | 0.070 |
Why?
|
| Collagen | 1 | 1993 | 2681 | 0.060 |
Why?
|
| Gamete Intrafallopian Transfer | 2 | 1996 | 27 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 1996 | 462 | 0.060 |
Why?
|
| Chromosome Disorders | 3 | 1998 | 510 | 0.060 |
Why?
|
| Safety Management | 1 | 2009 | 782 | 0.060 |
Why?
|
| Delayed-Action Preparations | 5 | 1994 | 967 | 0.060 |
Why?
|
| Infertility, Female | 2 | 2001 | 788 | 0.060 |
Why?
|
| Lipoma | 2 | 1996 | 334 | 0.060 |
Why?
|
| Hysterectomy | 3 | 2001 | 927 | 0.060 |
Why?
|
| Cloaca | 1 | 2003 | 52 | 0.050 |
Why?
|
| Mitosis | 2 | 2000 | 1207 | 0.050 |
Why?
|
| Pregnancy, High-Risk | 1 | 2003 | 120 | 0.050 |
Why?
|
| Clomiphene | 2 | 1993 | 71 | 0.050 |
Why?
|
| Receptors, Estrogen | 1 | 1990 | 2190 | 0.050 |
Why?
|
| Macrophages | 3 | 1993 | 5651 | 0.050 |
Why?
|
| Lymphocytes | 1 | 1989 | 2615 | 0.050 |
Why?
|
| Pregnancy | 12 | 2003 | 29140 | 0.050 |
Why?
|
| Streptococcus agalactiae | 1 | 2003 | 375 | 0.050 |
Why?
|
| Female | 46 | 2003 | 380020 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 7172 | 0.040 |
Why?
|
| Housekeeping, Hospital | 1 | 2018 | 17 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2009 | 2211 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 2003 | 636 | 0.040 |
Why?
|
| Blastomeres | 1 | 1998 | 28 | 0.040 |
Why?
|
| DNA, Neoplasm | 2 | 1994 | 1758 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 1990 | 13691 | 0.040 |
Why?
|
| Ultrasonography | 3 | 1994 | 5986 | 0.040 |
Why?
|
| Growth Substances | 1 | 2000 | 784 | 0.040 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 638 | 0.040 |
Why?
|
| Ovulation | 1 | 1998 | 189 | 0.040 |
Why?
|
| Oligospermia | 1 | 1997 | 56 | 0.040 |
Why?
|
| Humans | 47 | 2018 | 743811 | 0.040 |
Why?
|
| Dilatation and Curettage | 2 | 1994 | 56 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2001 | 660 | 0.040 |
Why?
|
| Zygote Intrafallopian Transfer | 1 | 1996 | 2 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 710 | 0.030 |
Why?
|
| Microinjections | 1 | 1997 | 326 | 0.030 |
Why?
|
| Drug Utilization Review | 1 | 2017 | 245 | 0.030 |
Why?
|
| Granulosa Cells | 2 | 1988 | 121 | 0.030 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1995 | 118 | 0.030 |
Why?
|
| Massachusetts | 2 | 2018 | 8660 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2017 | 202 | 0.030 |
Why?
|
| Leiomyomatosis | 1 | 1994 | 70 | 0.030 |
Why?
|
| Nucleolus Organizer Region | 1 | 1993 | 26 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1994 | 322 | 0.030 |
Why?
|
| Minisatellite Repeats | 1 | 1994 | 165 | 0.030 |
Why?
|
| Preoperative Care | 2 | 2001 | 2251 | 0.030 |
Why?
|
| Hysterosalpingography | 1 | 1993 | 30 | 0.030 |
Why?
|
| Flushing | 1 | 1993 | 48 | 0.030 |
Why?
|
| Hamartoma | 1 | 1995 | 238 | 0.030 |
Why?
|
| Spermatozoa | 1 | 1997 | 618 | 0.030 |
Why?
|
| Adult | 17 | 2003 | 213889 | 0.030 |
Why?
|
| Sterilization, Tubal | 1 | 1993 | 87 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2003 | 2265 | 0.030 |
Why?
|
| Microcomputers | 1 | 1993 | 147 | 0.030 |
Why?
|
| Tissue Adhesions | 2 | 1993 | 235 | 0.030 |
Why?
|
| Embryo, Mammalian | 1 | 1998 | 1702 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 1996 | 12020 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1993 | 683 | 0.030 |
Why?
|
| Ovarian Cysts | 1 | 1992 | 115 | 0.020 |
Why?
|
| Database Management Systems | 1 | 1993 | 270 | 0.020 |
Why?
|
| Buserelin | 1 | 1990 | 17 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 1993 | 564 | 0.020 |
Why?
|
| Quadruplets | 1 | 1990 | 9 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 1993 | 8637 | 0.020 |
Why?
|
| Coloring Agents | 1 | 1993 | 565 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 1993 | 5524 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2000 | 2942 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 1996 | 2029 | 0.020 |
Why?
|
| Culture Techniques | 1 | 1990 | 553 | 0.020 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 1989 | 94 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 1993 | 498 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 1164 | 0.020 |
Why?
|
| Leydig Cells | 1 | 1988 | 56 | 0.020 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 1988 | 55 | 0.020 |
Why?
|
| Macrophage Activation | 1 | 1992 | 559 | 0.020 |
Why?
|
| Muscle, Smooth | 1 | 1993 | 934 | 0.020 |
Why?
|
| Protozoan Infections | 1 | 1988 | 39 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 1991 | 709 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 1992 | 1147 | 0.020 |
Why?
|
| Vagina | 2 | 1994 | 825 | 0.020 |
Why?
|
| Receptors, Androgen | 1 | 1994 | 1055 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2760 | 0.020 |
Why?
|
| Endometriosis | 2 | 1993 | 838 | 0.020 |
Why?
|
| Pregnancy Outcome | 2 | 2003 | 2794 | 0.020 |
Why?
|
| Phagocytosis | 2 | 1993 | 1539 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1993 | 1374 | 0.020 |
Why?
|
| Genitalia, Female | 1 | 1988 | 146 | 0.020 |
Why?
|
| Amino Acids | 1 | 1993 | 1733 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1993 | 1459 | 0.020 |
Why?
|
| Oocytes | 1 | 1992 | 1186 | 0.020 |
Why?
|
| Growth Hormone | 1 | 1990 | 705 | 0.020 |
Why?
|
| Genital Diseases, Female | 1 | 1988 | 197 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1990 | 551 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 1993 | 6487 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2003 | 7270 | 0.020 |
Why?
|
| Pilot Projects | 2 | 1996 | 8316 | 0.020 |
Why?
|
| Headache | 1 | 1993 | 1224 | 0.020 |
Why?
|
| Lung Diseases | 1 | 1995 | 1887 | 0.020 |
Why?
|
| Prospective Studies | 5 | 1996 | 53250 | 0.010 |
Why?
|
| Cell Survival | 2 | 1993 | 5881 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 1992 | 3205 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1992 | 2969 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1990 | 5179 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2009 | 2453 | 0.010 |
Why?
|
| Tissue Preservation | 1 | 1982 | 180 | 0.010 |
Why?
|
| Freezing | 1 | 1982 | 303 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 1994 | 3706 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1994 | 10940 | 0.010 |
Why?
|
| Estrone | 2 | 1994 | 240 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 3 | 1994 | 6311 | 0.010 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2003 | 571 | 0.010 |
Why?
|
| Molecular Sequence Data | 4 | 1995 | 18107 | 0.010 |
Why?
|
| Recurrence | 1 | 1992 | 8337 | 0.010 |
Why?
|
| Cervix Uteri | 2 | 1994 | 590 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1993 | 7908 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 1993 | 13028 | 0.010 |
Why?
|
| Contrast Media | 1 | 1993 | 5301 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 1996 | 2649 | 0.010 |
Why?
|
| Middle Aged | 6 | 1998 | 213241 | 0.010 |
Why?
|
| Base Sequence | 3 | 1995 | 12798 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1993 | 12954 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 2003 | 707 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 2 | 1994 | 475 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2003 | 25609 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1996 | 4931 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 29777 | 0.010 |
Why?
|
| Prenatal Care | 1 | 2003 | 1092 | 0.010 |
Why?
|
| Hormones | 2 | 1990 | 889 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 10179 | 0.010 |
Why?
|
| Cells, Cultured | 4 | 1994 | 19232 | 0.010 |
Why?
|
| Placebos | 2 | 1990 | 1674 | 0.010 |
Why?
|
| Estradiol Congeners | 1 | 1994 | 28 | 0.010 |
Why?
|
| Retrospective Studies | 4 | 2003 | 77410 | 0.010 |
Why?
|
| Fertilization | 1 | 1996 | 196 | 0.010 |
Why?
|
| Norethindrone | 1 | 1994 | 59 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1995 | 299 | 0.010 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1994 | 98 | 0.010 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1994 | 73 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1994 | 326 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1994 | 237 | 0.010 |
Why?
|
| Incidence | 1 | 1992 | 20948 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 9944 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 1995 | 372 | 0.010 |
Why?
|
| Ethiodized Oil | 1 | 1993 | 34 | 0.010 |
Why?
|
| Diatrizoate Meglumine | 1 | 1993 | 83 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 1677 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 1992 | 39001 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 1 | 1994 | 211 | 0.010 |
Why?
|
| Hematocrit | 1 | 1994 | 636 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 1998 | 63042 | 0.010 |
Why?
|
| Pregnancy Rate | 1 | 1996 | 643 | 0.010 |
Why?
|
| Methylene Blue | 1 | 1993 | 155 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 2 | 1993 | 6170 | 0.010 |
Why?
|
| Twins | 1 | 1994 | 339 | 0.010 |
Why?
|
| Receptors, Mitogen | 1 | 1992 | 62 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1994 | 798 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 1992 | 65 | 0.010 |
Why?
|
| Cytoplasm | 1 | 1997 | 1536 | 0.010 |
Why?
|
| Colostrum | 1 | 1992 | 28 | 0.010 |
Why?
|
| Ovarian Diseases | 1 | 1993 | 139 | 0.010 |
Why?
|
| Leishmania donovani | 1 | 1992 | 65 | 0.010 |
Why?
|
| Molecular Probes | 1 | 1993 | 315 | 0.010 |
Why?
|
| Injections | 1 | 1994 | 839 | 0.010 |
Why?
|
| Time Factors | 3 | 2003 | 40038 | 0.010 |
Why?
|
| Clone Cells | 1 | 1994 | 1692 | 0.010 |
Why?
|
| Bone Density | 2 | 1994 | 3460 | 0.010 |
Why?
|
| Goserelin | 1 | 1990 | 129 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1994 | 850 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1994 | 1396 | 0.010 |
Why?
|
| Androstenedione | 1 | 1988 | 130 | 0.010 |
Why?
|
| Premedication | 1 | 1989 | 258 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 1992 | 730 | 0.010 |
Why?
|
| Fertility | 1 | 1993 | 779 | 0.000 |
Why?
|
| Subcellular Fractions | 1 | 1988 | 545 | 0.000 |
Why?
|
| Drug Combinations | 1 | 1993 | 1958 | 0.000 |
Why?
|
| Cholesterol, HDL | 1 | 1994 | 1813 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 2184 | 0.000 |
Why?
|
| Observer Variation | 1 | 1993 | 2592 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 4737 | 0.000 |
Why?
|
| Neoplastic Stem Cells | 1 | 1994 | 1376 | 0.000 |
Why?
|
| Spine | 1 | 1993 | 1144 | 0.000 |
Why?
|
| Ultrasonography, Interventional | 1 | 1994 | 1486 | 0.000 |
Why?
|
| Cilia | 1 | 1988 | 464 | 0.000 |
Why?
|
| Substrate Specificity | 1 | 1988 | 1802 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1988 | 2327 | 0.000 |
Why?
|
| Embolization, Therapeutic | 1 | 1994 | 1392 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1994 | 4326 | 0.000 |
Why?
|
| Fasting | 1 | 1990 | 1590 | 0.000 |
Why?
|
| Receptors, LH | 1 | 1982 | 19 | 0.000 |
Why?
|
| Alleles | 1 | 1994 | 6934 | 0.000 |
Why?
|
| Up-Regulation | 1 | 1992 | 4221 | 0.000 |
Why?
|
| Intraoperative Complications | 1 | 1989 | 1195 | 0.000 |
Why?
|
| Diagnostic Errors | 1 | 1988 | 1256 | 0.000 |
Why?
|
| Societies, Medical | 1 | 1993 | 3740 | 0.000 |
Why?
|
| Culture Media | 1 | 1982 | 909 | 0.000 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1996 | 8430 | 0.000 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1982 | 745 | 0.000 |
Why?
|
| Blood | 1 | 1982 | 596 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1991 | 13809 | 0.000 |
Why?
|
| Rats | 2 | 1988 | 24250 | 0.000 |
Why?
|
| Testosterone | 1 | 1988 | 2297 | 0.000 |
Why?
|
| Hemorrhage | 1 | 1989 | 3458 | 0.000 |
Why?
|
| DNA | 1 | 1991 | 7295 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1991 | 7719 | 0.000 |
Why?
|
| Epithelial Cells | 1 | 1988 | 3690 | 0.000 |
Why?
|
| Risk Factors | 1 | 2003 | 72252 | 0.000 |
Why?
|
| Receptors, Cell Surface | 1 | 1982 | 2865 | 0.000 |
Why?
|
| Swine | 1 | 1982 | 5909 | 0.000 |
Why?
|
| Animals | 3 | 1992 | 168660 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1989 | 15281 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 1994 | 35409 | 0.000 |
Why?
|
| Male | 2 | 1997 | 349776 | 0.000 |
Why?
|
| United States | 1 | 1993 | 69859 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1982 | 11478 | 0.000 |
Why?
|